Even under the best circumstances, conducting robust, high-quality clinical trials can pose considerable scientific, financial, and logistical challenges. For those working on diseases that can affect the world’s most vulnerable people, such as TB, malaria, and HIV, these customary hurdles come with additional complexities. Researchers and organizations working in resource-limited settings and with underserved populations often must develop relationships with new and sometimes untested manufacturing partners, navigate unstable political environments, and contend with problems ranging from inadequate facilities and equipment to electricity, hygiene, and connectivity issues. Launched in 2009, the Global Health Clinical Consortium (GHCC) brings together leaders from several research organizations that focus on diseases that affect vulnerable populations in low- and middle-income countries (LMICs) to help mitigate these obstacles, catalyze more top-flight clinical trials, and leverage the power and possibilities that arise from joint effort.

The eight Product Development Partners (PDPs) that today comprise the GHCC (including MMV) are currently conducting more than 72 ongoing and planned trials to develop vaccines, microbicides, preventatives, therapeutic products, and diagnostics for more than 17 disease areas at nearly 422 clinical research sites. Download the report for an overview of our impact.